Phase II Study of XmAb23104 (Targeting PD-1 and ICOS), in Patients With Advanced Sarcoma
Latest Information Update: 27 Sep 2024
At a glance
- Drugs Izuralimab (Primary)
- Indications Alveolar soft part sarcoma; Chondrosarcoma; Fibrosarcoma; Leiomyosarcoma; Liposarcoma; Perivascular epithelioid cell tumours; Sarcoma
- Focus Therapeutic Use
Most Recent Events
- 19 Sep 2024 Status changed from active, no longer recruiting to discontinued.
- 04 Dec 2023 Planned End Date changed from 6 Apr 2028 to 6 Apr 2025.
- 04 Dec 2023 Planned primary completion date changed from 6 Apr 2028 to 6 Apr 2025.